CIA
ACOR

Capital Impact Advisors’s Acorda Therapeutics ACOR Stock Holding History

Capital Impact Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-75
Closed -$169K – 232
2016
Q4 		$169K Hold
75
– – 0.07% 214
2016
Q3 		$188K Hold
75
– – 0.08% 218
2016
Q2 		$230K Hold
75
– – 0.11% 214
2016
Q1 		$238K Hold
75
– – 0.11% 215
2015
Q4 		$385K Buy
+75
New +$328K 0.18% 224

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Capital Impact Advisors's ACOR Position: Q1 2017 in Review

Capital Impact Advisors sold out of Acorda Therapeutics (ACOR) in Q1 2017, closing a stake of 75 shares — an estimated $169K sold.

Capital Impact Advisors first reported a position in ACOR in Q4 2015 and held it in 5 quarters. The position peaked at $385K in Q4 2015. 178 funds tracked by Wall St. Rank hold ACOR as of Q1 2017.

  • Capital Impact Advisors reported no remaining Acorda Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Capital Impact Advisors sold 75 Acorda Therapeutics shares in Q1 2017, an estimated $169K.
  • Capital Impact Advisors first reported a position in Acorda Therapeutics in Q4 2015 and held it in 5 quarters.
  • Capital Impact Advisors's Acorda Therapeutics position peaked at $385K in Q4 2015.
  • 178 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2017.

Based on Capital Impact Advisors's 13F filing for Q1 2017, filed 19 Apr 2017.